C-Path welcomes Kay Holcombe to its Board of Directors
January 17, 2018
TUCSON, Ariz., January 17, 2018 — The Critical Path Institute (C-Path) is pleased to welcome Kay Holcombe to its Board of Directors. Recently retired as Senior Vice President for Science Policy at the Biotechnology Innovation Organization (BIO), Ms. Holcombe brings to the Board her extensive experience in health care and regulatory policy, a history of collaboration with US regulatory agencies, and broad knowledge of government initiatives that affect the biotechnology and pharmaceutical industries.
“The Board is very pleased to welcome Kay,” said Dr. Timothy R. Franson, Chair of C-Path’s Board of Directors. “The skills, insights, and cross-sector knowledge Kay has acquired over her career, as well as her interpersonal strengths, will prove important assets as C-Path’s collaborative work continues to expand and evolve.”
At BIO, Ms. Holcombe worked with government relations, policy, and legal staff, as well as with principals of BIO member companies, to develop and implement policies that advance public health, and to develop appropriate responses to government initiatives that affect the industry broadly. Prior to that position, she was Vice President, FDA Alliances and Federal Agency Relations, at Sanofi, and Vice President for Government Relations at Genzyme Corporation. As Executive Vice President of the government relations firm Policy Directions Inc., prior to joining Sanofi, Ms. Holcombe spent eight years working in health-care-related strategic planning and regulatory advocacy, providing advice and assistance at federal regulatory and funding agencies, and in the US Congress.
“We are fortunate to include on our Board someone with the policy experience and familiarity with regulatory initiatives that Kay possesses,” said Dr. Martha Brumfield, President and CEO of C-Path. “C-Path continues to work closely with regulators worldwide to provide appropriate evidence and data to advance novel tools that will accelerate drug development and regulatory review. Kay’s firsthand knowledge of the needs of both industry and FDA is invaluable as C-Path continues to be at the forefront of regulatory science.”
Kay received her BS in chemistry education from the University of Illinois and her MS in chemistry from the University of Virginia. She graduated with honors and was elected to Phi Beta Kappa, Phi Kappa Phi, and Iota Sigma Pi.
For biographies of the C-Path Board of Directors, click here.
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 with public and private philanthropic support from the Arizona community, Science Foundation Arizona, and the US Food and Drug Administration (FDA). C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established 12 global, public-private partnerships that currently include over 1,450 scientists from government and regulatory agencies, academia, patient advocacy organizations, and dozens of major pharmaceutical companies. C-Path is headquartered in Tucson, Arizona. For more information, visit www.c-path.org.